BLRX
BioLineRx Ltd.
There isn't enough reported data to score BLRX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BLRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
BLRX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BLRX PE Valuation
BLRX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect BLRX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.00 | +$0.01 |
| Q2 2025 | -$0.01 | +$18.05 |
| Q4 2024 | -$0.01 | +$37.73 |
| Q2 2024 | -$18.06 | +$9.36 |
| Q4 2023 | -$37.74 | -$20.70 |
| Q3 2023 | -$32.40 | -$13.86 |
| Q2 2023 | -$27.42 | -$9.36 |
| Q1 2023 | -$21.48 | -$3.42 |
BLRX has the stronger earnings trend. Trailing diluted EPS is down 100% for BLRX versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $621K | -96% |
| Q2 2025 | $559K | -95% |
| Q4 2024 | $16.7M | +248% |
HIMS has the stronger quarterly revenue trend. Revenue is down 87% for BLRX versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -901% | -514 points |
| Q2 2025 | -840% | N/A |
| Q4 2024 | -59% | N/A |
| Q2 2024 | -87% | N/A |
| Q4 2023 | -387% | N/A |
BLRX's operating margin was −901% last quarter, down 514 points from the same quarter a year ago, near the bottom of its range since 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.3M | +$13.1M |
| Q2 2025 | -$2.8M | +$22.7M |
| Q4 2024 | -$18.4M | -471% |
| Q2 2024 | -$25.5M | -$15.7M |
| Q4 2023 | $5M | +$10.9M |
| Q3 2023 | -$9.9M | -$1.2M |
| Q2 2023 | -$9.8M | -$3.5M |
| Q1 2023 | -$8.1M | -$2.5M |
BLRX has the stronger cash trend. Its trailing FCF is down 81% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
BLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +171M shares |
| 1 year | +159111% | +2.5B shares |
| 3 years | +208682% | +2.5B shares |
| 5 years | +993157% | +2.5B shares |
| Available history | +1393119% | +2.5B shares |
BLRX has 2.5B diluted shares, up 159111% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BLRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BLRX Net Leverage
BLRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 1.7 | Oversold |
BLRX's weekly RSI is 23 (oversold) and its Stochastic is 2 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BLRX PE vs Healthcare Sector
BLRX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.04 | 34% below |
| 20 week MA | $2.49 | 46% below |
| 50 week MA | $2.74 | 51% below |
| 100 week MA | $3.43 | 61% below |
| 200 week MA | $22.8 | 94% below |
BLRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $91.2 | $103.2 | +13% |
| 2021 | $103.2 | $87.6 | -15% |
| 2022 | $87.6 | $23.2 | -74% |
| 2023 | $23.2 | $62.8 | +171% |
| 2024 | $62.8 | $8.86 | -86% |
| 2025 | $8.86 | $2.90 | -67% |
| 2026 YTD | $2.90 | $1.35 | -53% |
BLRX's yearly returns have swung widely, from +171% in 2023 to −86% in 2024. It's down 53% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BLRX on returns for 2026, with the stronger performance.